{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"To evaluate the immunological impact of the ARG1-18,19,20 peptide vaccines using blood samples and tumor biopsies.","groups":[{"description":"One ARG1-vaccine every third week for 45 weeks.\n\nARG1-18,19,20: 300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide","id":"OG000","title":"ARG1-18,19,20 Peptide Vaccine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Development of a reactive T cell response against at least one of the ARG1 peptides during treatment using interferon-gamma ELISPOT","reportingStatus":"POSTED","timeFrame":"project blood samples were taken at baseline and every 3 months for a maximum of 1,5 year. Tumor biopsies were taken at baseline and after 3 months if possible.","title":"Immune Responses","type":"SECONDARY","unitOfMeasure":"Participants"}